Is methamphetamine abuse a risk factor in parkinsonism? (Q34518985)

2 August 2017

1 reference

title

Is methamphetamine abuse a risk factor in parkinsonism? (English)

1 reference

2 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

Guilarte TR

1

1 reference

2 August 2017

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

22

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

725-731

1 reference

Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Regulation of DOPA decarboxylase activity in brain of living rat.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

New insights into the cause of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Methamphetamine-induced hyperthermia in mice: examination of dopamine depletion and heat-shock protein induction

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

6-[18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Withdrawal of repeated cocaine decreases autoradlographic [3H]mazindol-labelling of dopamine transporter In rat nucleus aecumbens

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Treatment of mice with methamphetamine produces cell loss in the substantia nigra

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Parkinson disease in twins: an etiologic study

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and DirectIn VitroDeterminations

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Striatal dopamine nerve terminal markers in human, chronic methamphetamine users

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Long-term effects of chronic methamphetamine administration in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors

1 reference

https://api.crossref.org/works/10.1016/S0161-813X(01)50046-8

7 January 2021

10.1016/S0161-813X(01)00046-8

Identifiers

DOI

1 reference

2 August 2017

1 reference